Capricor Therapeutics Inc
NASDAQ:CAPR

Watchlist Manager
Capricor Therapeutics Inc Logo
Capricor Therapeutics Inc
NASDAQ:CAPR
Watchlist
Price: 18.215 USD -1.49%
Market Cap: 592.7m USD
Have any thoughts about
Capricor Therapeutics Inc?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Capricor Therapeutics Inc

Revenue
27.2m USD
Operating Expenses
-57.2m USD
Operating Income
-30m USD
Other Expenses
2.1m USD
Net Income
-27.9m USD

Margins Comparison
Capricor Therapeutics Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
Capricor Therapeutics Inc
NASDAQ:CAPR
591.4m USD
-110%
-103%
US
Abbvie Inc
NYSE:ABBV
333.6B USD
29%
10%
US
Amgen Inc
NASDAQ:AMGN
173B USD
20%
10%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.8B USD
41%
-5%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
111.1B USD
31%
32%
US
Gilead Sciences Inc
NASDAQ:GILD
108.5B USD
37%
4%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
-392%
AU
CSL Ltd
ASX:CSL
145.3B AUD
26%
18%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
38B USD
4%
-3%
KY
Beigene Ltd
SSE:688235
248.5B CNY
-30%
-20%
Country US
Market Cap 591.4m USD
Operating Margin
-110%
Net Margin
-103%
Country US
Market Cap 333.6B USD
Operating Margin
29%
Net Margin
10%
Country US
Market Cap 173B USD
Operating Margin
20%
Net Margin
10%
Country US
Market Cap 124.8B USD
Operating Margin
41%
Net Margin
-5%
Country US
Market Cap 111.1B USD
Operating Margin
31%
Net Margin
32%
Country US
Market Cap 108.5B USD
Operating Margin
37%
Net Margin
4%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Net Margin
-392%
Country AU
Market Cap 145.3B AUD
Operating Margin
26%
Net Margin
18%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 38B USD
Operating Margin
4%
Net Margin
-3%
Country KY
Market Cap 248.5B CNY
Operating Margin
-30%
Net Margin
-20%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Capricor Therapeutics Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Capricor Therapeutics Inc
NASDAQ:CAPR
591.4m USD
-393%
-66%
-224%
-1 048%
US
Abbvie Inc
NYSE:ABBV
333.6B USD
54%
4%
16%
12%
US
Amgen Inc
NASDAQ:AMGN
173B USD
49%
3%
9%
8%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.8B USD
-3%
-2%
25%
-84%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
111.1B USD
17%
13%
14%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
108.5B USD
5%
2%
23%
13%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
145.3B AUD
16%
7%
12%
9%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
38B USD
35%
-2%
4%
9%
KY
Beigene Ltd
SSE:688235
248.5B CNY
-17%
-11%
-23%
-46%
Country US
Market Cap 591.4m USD
ROE
-393%
ROA
-66%
ROCE
-224%
ROIC
-1 048%
Country US
Market Cap 333.6B USD
ROE
54%
ROA
4%
ROCE
16%
ROIC
12%
Country US
Market Cap 173B USD
ROE
49%
ROA
3%
ROCE
9%
ROIC
8%
Country US
Market Cap 124.8B USD
ROE
-3%
ROA
-2%
ROCE
25%
ROIC
-84%
Country US
Market Cap 111.1B USD
ROE
17%
ROA
13%
ROCE
14%
ROIC
17%
Country US
Market Cap 108.5B USD
ROE
5%
ROA
2%
ROCE
23%
ROIC
13%
Country US
Market Cap 94.1B EUR
ROE
-877%
ROA
-67%
ROCE
-73%
ROIC
-182%
Country AU
Market Cap 145.3B AUD
ROE
16%
ROA
7%
ROCE
12%
ROIC
9%
Country US
Market Cap 39.3B EUR
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 38B USD
ROE
35%
ROA
-2%
ROCE
4%
ROIC
9%
Country KY
Market Cap 248.5B CNY
ROE
-17%
ROA
-11%
ROCE
-23%
ROIC
-46%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top